Braveheart Bio, Inc. (BRVE) vs Taysha Gene Therapies, Inc. (TSHA)

A side-by-side comparison of Braveheart Bio, Inc. and Taysha Gene Therapies, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BRVE

Braveheart Bio, Inc.

$1.39B

$19.73HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT

TSHA

Taysha Gene Therapies, Inc.

$1.40B

$4.38HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT

Total return — BRVE vs TSHA

growth of $100 · dividends reinvested · last 1y

BRVE +18.6% (+18.6%/yr)TSHA -27.6% (-27.6%/yr)BRVE compounded faster over this window

BRVE TSHA

Metrics side by side

Total return (annualized)

Metric	BRVE	TSHA
Total return (1Y)	N/A	1.59%
Total return CAGR (3Y)	N/A	21.23%
Total return CAGR (5Y)	N/A	-25.17%

BRVE is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full BRVE analysis Full TSHA analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.